Brokers expect Genmab A/S (NASDAQ:GMAB) to post quarterly sales of $300.58 million


Wall Street analysts predict that Genmab A/S (NASDAQ: GMABGet a rating) will report $300.58 million in sales for the current fiscal quarter, according to Zacks Investment Research. Four analysts have released earnings estimates for Genmab A/S, with the highest sales estimate at $343.39 million and the lowest estimate at $251.40 million. Genmab A/S recorded sales of $256.24 million in the same quarter last year, indicating a positive growth rate of 17.3% year-over-year. The company is expected to release its next quarterly earnings report on Monday, January 1.

According to Zacks, analysts expect Genmab A/S to report annual revenue of $1.77 billion for the current fiscal year, with estimates ranging from $1.70 billion to $1.85 billion. dollars. For next year, analysts expect the company to record sales of $2.26 billion, with estimates ranging from $2.12 billion to $2.55 billion. Zacks sales averages are an average based on a survey of analysts who provide coverage for Genmab A/S.

Genmab A/S (NASDAQ: GMABGet a rating) last released its quarterly earnings data on Wednesday, February 16. The company reported earnings per share of $0.17 for the quarter, beating the consensus estimate of $0.13 by $0.04. The company posted revenue of $402.74 million for the quarter, compared to $387.16 million expected by analysts. Genmab A/S posted a net margin of 35.58% and a return on equity of 14.23%.

A number of equity research analysts have weighed in on GMAB shares recently. Morgan Stanley lowered its price target on Genmab A/S shares from $33.00 to $30.00 and set an “underweight” rating on the stock in a Tuesday, April 12 report. HC Wainwright reiterated a “buy” rating and posted a $47.00 price target on Genmab A/S shares in a research note on Thursday, March 17. Guggenheim downgraded shares of Genmab A/S from a “buy” rating to a “neutral” rating in a Monday, Jan. 3 research note. JPMorgan Chase & Co. lowered its price target on Genmab A/S shares from 3,200.00 to 3,100.00 in a Friday, February 25 research note. Finally, UBS Group upgraded Genmab A/S shares from a “neutral” rating to a “buy” rating in a Wednesday, March 16 research note. Four analysts have assigned the stock a sell rating, three have issued a hold rating and six have assigned the company a buy rating. According to MarketBeat, Genmab A/S currently has a consensus rating of “Hold” and a consensus price target of $480.86.

Several hedge funds have recently changed their holdings in GMAB. Ellevest Inc. increased its stake in Genmab A/S by 21.1% in the 1st quarter. Ellevest Inc. now owns 7,516 shares of the company worth $272,000 after purchasing an additional 1,311 shares during the period. Cim LLC increased its stake in Genmab A/S by 1.7% in the 1st quarter. Cim LLC now owns 27,994 shares of the company worth $1,002,000 after purchasing an additional 465 shares during the period. Veriti Management LLC increased its stake in Genmab A/S by 44.7% in the 1st quarter. Veriti Management LLC now owns 10,054 shares of the company worth $364,000 after purchasing an additional 3,104 shares during the period. Castleview Partners LLC bought a new position in Genmab A/S in Q4 worth $211,000. Finally, Sentinel Trust Co. LBA bought a new position in Genmab A/S in Q4 worth $219,000. Institutional investors hold 6.09% of the company’s shares.

GMAB Stock opened at $37.48 on Friday. The stock has a market capitalization of $24.64 billion, a PE ratio of 51.34, a growth price-earnings ratio of 1.67 and a beta of 1.04. The company’s 50-day moving average is $34.81 and its 200-day moving average is $37.86. Genmab A/S has a 1 year minimum of $30.08 and a 1 year maximum of $49.07.

About Genmab A/S (Get a rating)

Genmab A/S develops therapeutic antibodies for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphocytic leukemia (CLL) and multiple sclerosis; and amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.

Featured Articles

Get a Free Copy of Zacks’ Research Report on Genmab A/S (GMAB)

For more information on Zacks Investment Research’s research offerings, visit Zacks.com

Earnings history and estimates for Genmab A/S (NASDAQ: GMAB)



Get news and reviews for Genmab A/S Daily – Enter your email address below to receive a concise daily summary of breaking news and analyst ratings for Genmab A/S and related companies with MarketBeat.com’s free daily email newsletter.

Comments are closed.